NasdaqGS:IDYABiotechs
IDEAYA Biosciences (IDYA) Q4 Loss Of US$83.3 Million Tests Bullish Growth Narrative
IDEAYA Biosciences (IDYA) has wrapped up FY 2025 with Q4 revenue of US$10.9 million, a basic EPS loss of US$0.94, and net income excluding extra items at a loss of US$83.3 million. Trailing twelve month figures show revenue of US$218.7 million and a basic EPS loss of US$1.28. Over recent quarters, the company’s revenue moved from US$7.0 million in Q4 2024 to US$207.8 million in Q3 2025 before landing at US$10.9 million in Q4 2025. Basic EPS ranged from a loss of US$1.49 in Q4 2024 to a profit...